3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Ovarian Neoplasms
10
Breast Neoplasms
5
Sarcoma
3
Prostatic Neoplasms
3
Fallopian Tube Neoplasms
3
Neoplasm Metastasis
2
Carcinoma, Non-Small-Cell Lung
2
Triple Negative Breast Neoplasms
1
Sarcoma, Ewing
1
Recurrence
1
Platinum-sensitive Relapsed Ovarian Cancer
1
Osteosarcoma
1
Nasopharyngeal Neoplasms
1
Nasopharyngeal Carcinoma
1
Metastatic Castration Resistant Prostate Cancer
1
Kenny-Caffey syndrome, Type 1
1
Her-2 Negative Breast Cancer
1
Glioblastoma
1
Female Breast Cancer Patients
1
Esophageal Squamous Cell Carcinoma
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Breast Cancer Metastatic
1
Advanced Solid Tumors
1
Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer
1
Interventions
Ifosfamide
15
Methotrexate
12
Doxorubicin
12
Filgrastim
10
Cisplatin
10
Cyclophosphamide
9
Etoposide
8
Gemcitabine
7
cabozantinib
6
apatinib
6
Magnetic Resonance Spectroscopy
6
Leucovorin
6
X-Rays
5
Specimen Handling
5
Sirolimus
5
Phantoms, Imaging
5
Nivolumab
5
Neoadjuvant Therapy
5
camrelizumab
4
Vincristine
4
Topotecan
4
Radiotherapy
4
Nuclear Medicine Department, Hospital
4
Drug Therapy
4
Docetaxel
4
Biopsy
4
regorafenib
3
palbociclib
3
olaparib
3
mifamurtide
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Osteosarcoma
×
fluzoparib
×
Clear all
NCT06074692
2023-10-31
PRIMA
Ruijin Hospital
Phase 2
Recruiting
86 enrolled